Preventive effect of 20(S)-ginsenoside Rg3 against lipopolysaccharide-induced hepatic and renal injury in rats.
The preventive effect of 20(S)-ginsenoside Rg(3) (20(S)-Rg(3)) on lipopolysaccharide (LPS)-induced oxidative tissue injury in rats was investigated in this study. The elevated serum nitrite/nitrate, glutamic oxaloacetic transaminase, glutamic pyruvic transaminase and creatinine levels in LPS-treated control rats were significantly decreased following 15 consecutive days of 20(S)-Rg(3) administration. In addition, thiobarbituric acid-reactive substance levels in the serum, liver and kidney were dose-dependently lower in 20(S)-Rg(3)-treated groups than in the LPS-treated control group. The nuclear factor-kappaB (NF-kappaB), cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS) and heme oxygenase-1 (HO-1) protein expressions in the liver and kidney were significantly increased by LPS treatment. However, the 20(S)-Rg(3) administrations significantly decreased these protein expressions except for HO-1 in the liver. On the other hand, in the kidney, oral administration of 20(S)-Rg(3) showed a tendency to reduce NF-kappaB and iNOS protein expressions and also significantly reduced the elevated COX-2 and HO-1 protein expressions at a dose of 10 mg/kg body weight/day. All these results suggest the preventive effect of 20(S)-Rg(3) against LPS-induced acute oxidative damage in the liver and kidney and the preventive effect of 20(S)-Rg(3) administration against LPS toxicity was thought to be more predominant in the liver than kidney.
Kang
Ki Sung
KS
Institute of Natural Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.
Kim
Hyun Young
HY
Yamabe
Noriko
N
Park
Jeong Hill
JH
Yokozawa
Takako
T
D000284:Administration, Oral; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000737:chemistry / Q000494:pharmacology; D000975:Antioxidants / Q000737:chemistry / Q000378:metabolism; D036145:Ginsenosides / Q000737:chemistry* / Q000494:pharmacology*; D051547:Heme Oxygenase-1 / Q000378:metabolism; D007668:Kidney / Q000293:injuries / Q000378:metabolism / Q000473:pathology*; D008070:Lipopolysaccharides / Q000737:chemistry*; D008099:Liver / Q000293:injuries / Q000378:metabolism*; D008297:Male; D008956:Models, Chemical; D016328:NF-kappa B / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar
D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D036145:Ginsenosides; D008070:Lipopolysaccharides; D016328:NF-kappa B; C097367:ginsenoside Rg3; D052247:Nitric Oxide Synthase Type II; D051547:Heme Oxygenase-1